Status:
RECRUITING
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
Lead Sponsor:
GBG Forschungs GmbH
Collaborating Sponsors:
AstraZeneca
Conditions:
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Detailed Description
The evaluation of CCCA in the HR+/HER2- invasive lobular breast cancer patient population allows assessment of treatment efficacy with an achievable sample size of HR+/HER2- breast cancer patients wit...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
December 4 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06607757
Start Date
December 4 2024
End Date
August 31 2026
Last Update
April 2 2025
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Haematologie-Onkologie im Zentrum MVZ GmbH
Augsburg, Germany, 86150
2
Charité
Berlin, Germany, 10117
3
Onkologische Schwerpunktpraxis - Studiengesellschaft Onkologie Bielefeld GbR
Bielefeld, Germany, 33604
4
Hämato-Onkologie im Medicum - Onkologie und Hämatologie
Bremen, Germany, 28209